BH shares rose 3.95% to 197.50 baht after reporting second-quarter 2026 net profit of 1.89 billion baht, up 1.7% from a year earlier and 5.5% from the previous quarter, in line with research expectations. The result was supported by revenue from international patients, which increased 7.1% year-on-year, led by Myanmar, the Middle East, and the United States, while Thai patient revenue declined 2.2%. The company announced an interim dividend of 4.00 baht per share, with the ex-dividend date set for August 28. Asia Plus Securities upgraded its recommendation to buy from speculative, with a 2027 target price of 220.00 baht per share, citing expectations for stronger second-half performance driven by a recovery in international patients and the high season for Thai patients.
Bumrungrad Hospital PCLQ2 earnings beat expectations and broker upgrade to buy with higher target price.
